The Barbara Ann Karmanos Cancer Institute, headquartered in Detroit, is the largest cancer research and provider network in Michigan and has 16 treatment locations. It is one of 51 National Cancer Institute-designated comprehensive cancer treatment and research centers in the United States.

There are 123 beds in Karmanos Cancer Institute/BMT.

During the past decade, Karmanos Cancer Institute/BMT conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 6 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Karmanos Cancer Institute/BMT" #1 collaborator was "Blood and Marrow Transplant Clinical Trials Network" with 7 trials as a collaborator, "National Cancer Institute (NCI)" with 7 trials as a collaborator, "National Marrow Donor Program" with 5 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 4 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Karmanos Cancer Institute/BMT" are "Follicular Lymphoma" (2 trials), "Multiple Myeloma" (2 trials), "Acute Leukemia" (1 trials), "Acute Lymphocytic Leukemia" (1 trials) and "Acute Myelogenous Leukemia" (1 trials). Many other conditions were trialed in "Karmanos Cancer Institute/BMT" in a lesser frequency.

Most popular intervention types in "Karmanos Cancer Institute/BMT" are "Drug" (5 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (2 trials), "Allogeneic Hematopoietic Cell Transplant" (1 trials), "Allogeneic transplant" (1 trials), "Autologous transplant" (1 trials) and "Bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Karmanos Cancer Institute/BMT" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Karmanos Cancer Institute/BMT". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Karmanos Cancer Institute/BMT, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Karmanos Cancer Institute/BMT, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".